Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2007 1
2008 2
2009 3
2010 6
2011 4
2012 8
2013 7
2014 6
2015 7
2016 7
2017 5
2018 11
2019 9
2020 4
2021 5
2022 9
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. Among authors: machida n. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer.
Muro K, Shitara K, Yamaguchi K, Yoshikawa T, Satake H, Hara H, Sugimoto N, Machida N, Goto M, Kawakami H, Amagai K, Omuro Y, Esaki T, Hironaka S, Nishina T, Komatsu Y, Matsubara H, Shiratori S, Han S, Satoh T, Ohtsu A. Muro K, et al. Among authors: machida n. J Gastrointest Cancer. 2023 Sep;54(3):951-961. doi: 10.1007/s12029-023-00920-9. Epub 2023 Apr 10. J Gastrointest Cancer. 2023. PMID: 37037952 Free PMC article. Clinical Trial.
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Hayashi K, Furuta M, Furusawa K, Hamaguchi T, Watanabe M, Inokuchi Y, Onuma S, Hashimoto I, Suematsu H, Nagasawa S, Kanematsu K, Yamada T, Notsu A, Ogata T, Oshima T, Machida N, Furuse J, Maeda S. Hayashi K, et al. Among authors: machida n. Anticancer Res. 2023 Jun;43(6):2831-2840. doi: 10.21873/anticanres.16452. Anticancer Res. 2023. PMID: 37247885
Combination of oligo-fractionated irradiation with nivolumab can induce immune modulation in gastric cancer.
Mimura K, Ogata T, Nguyen PHD, Roy S, Kared H, Yuan YC, Fehlings M, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, Machida N, Yamada T, Watanabe Y, Tamaki T, Fujikawa H, Inokuchi Y, Hayase S, Hanayama H, Saze Z, Katoh H, Takahashi F, Oshima T, Goel A, Nardin A, Suzuki Y, Kono K. Mimura K, et al. Among authors: machida n. J Immunother Cancer. 2024 Jan 30;12(1):e008385. doi: 10.1136/jitc-2023-008385. J Immunother Cancer. 2024. PMID: 38290769 Free PMC article.
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer.
Mimura K, Ogata T, Yoshimoto Y, Yoshida D, Nakajima S, Sato H, Machida N, Yamada T, Watanabe Y, Tamaki T, Fujikawa H, Inokuchi Y, Hayase S, Hanayama H, Saze Z, Katoh H, Takahashi F, Oshima T, Suzuki Y, Kono K. Mimura K, et al. Among authors: machida n. Commun Med (Lond). 2023 Aug 15;3(1):111. doi: 10.1038/s43856-023-00343-4. Commun Med (Lond). 2023. PMID: 37582945 Free PMC article.
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.
Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group. Fuchs CS, et al. Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Lancet Oncol. 2019. PMID: 30718072 Clinical Trial.
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab.
Suematsu H, Kano K, Yamada T, Hashimoto I, Watanabe H, Takahashi K, Watanabe M, Hayashi K, Kaneta Y, Furuta M, Inokuchi Y, Machida N, Aoyama T, Tamagawa H, Yukawa N, Rino Y, Masuda M, Ogata T, Oshima T. Suematsu H, et al. Among authors: machida n. Anticancer Res. 2022 Mar;42(3):1535-1540. doi: 10.21873/anticanres.15626. Anticancer Res. 2022. PMID: 35220249
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study).
Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, Watanabe M, Imamura H, Kinoshita T, Yasuda T, Hihara J, Fukuda H, Yoshikawa T, Boku N, Terashima M. Tokunaga M, et al. Among authors: machida n. Gastric Cancer. 2024 May;27(3):580-589. doi: 10.1007/s10120-024-01467-9. Epub 2024 Jan 19. Gastric Cancer. 2024. PMID: 38243037 Clinical Trial.
87 results